RLMD vs. ZIOP, VRCA, STTK, ACIU, ORGO, AMRN, ANRO, PGEN, SKYE, and NKTX
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include ZIOPHARM Oncology (ZIOP), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), AC Immune (ACIU), Organogenesis (ORGO), Amarin (AMRN), Alto Neuroscience (ANRO), Precigen (PGEN), Skye Bioscience (SKYE), and Nkarta (NKTX). These companies are all part of the "medical" sector.
ZIOPHARM Oncology (NASDAQ:ZIOP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
Relmada Therapeutics has a consensus price target of $25.00, indicating a potential upside of 733.33%.
Relmada Therapeutics' return on equity of -92.84% beat ZIOPHARM Oncology's return on equity.
51.0% of ZIOPHARM Oncology shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 5.2% of ZIOPHARM Oncology shares are held by insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Relmada Therapeutics is trading at a lower price-to-earnings ratio than ZIOPHARM Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Relmada Therapeutics had 3 more articles in the media than ZIOPHARM Oncology. MarketBeat recorded 3 mentions for Relmada Therapeutics and 0 mentions for ZIOPHARM Oncology. ZIOPHARM Oncology's average media sentiment score of 0.80 beat Relmada Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.
ZIOPHARM Oncology has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
ZIOPHARM Oncology received 374 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 54.62% of users gave ZIOPHARM Oncology an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Summary
ZIOPHARM Oncology beats Relmada Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
